Sotorasib + Panitumumab Beneficial for Chemorefractory Metastatic CRC

TUESDAY, Oct. 24, 2023-- For patients with chemorefractory metastatic colorectal cancer, the KRAS G12C inhibitor sotorasib in combination with the epidermal growth factor receptor inhibitor panitumumab results in longer progression-free survival...